To evaluate the neutralizing activity of Navicixizumab against VEGF. Co-incubation of Navicixizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Navicixizumab can neutralize VEGF-165, and the IC50 was 7.957 nM.

Navicixizumab bound to huDLL4-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Navicixizumab bound to huDLL4-FL-HEK293 cells, and the EC50 was 4.603 nM.

Navicixizumab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huVEGFA-His, and the EC50 was 0.020 nM.

Navicixizumab bound to DLL4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huDLL4-His, and the EC50 was 0.033 nM.

The purity of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 97.99%, determined by SEC-HPLC.

Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.